
Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Patent Profiles
-
By Christopher P. Singer — In a January 24, 2007 press release, EvoGenix Ltd announced that U.S. Patent No. 7,166,697, titled "V-like domain binding molecules" has been granted by the U.S. Patent Office. According to EvoGenix, the patent covers a protein technology termed "Evibodies®," which are similar to antibodies and are useful in…
-
By Christopher P. Singer — In a December 14, 2006 press release, Mirus Bio Corporation announced that U.S. Patent No. 7,148,205, titled "Intravascular Delivery of Non-Viral Nucleic Acid" has been granted by the U.S. Patent Office. According to Mirus Bio, the patent covers a technology for the administration of molecules that can induce RNA…
-
By Christopher P. Singer — In a November 27, 2006 press release Cytogen announced that U.S. Patent No. 7,135,457 issued for oral drug delivery agents that are random peptide compositions that bind to gastro-intestinal tract (GIT) transport receptors. These agents aid in the transport of active agents from the lumen of mammalian GIT…
-
By Christopher P. Singer — In a November 22, 2006 press release, Introgen Therapeutics, Inc. (INGN) announced that it has been awarded U.S. Patent No. 7,125,706, titled "An Improved Method for the Production and Purification of Adenoviral Vectors." This patent represents the third issued U.S. patent in Introgen’s adenoviral vector intellectual property portfolio. …